Japanese Scientists Unveil New Mesothelioma Treatment Strategy, According to Surviving Mesothelioma

Share Article

Researchers say RNA manipulation may be key to boosting the effectiveness of chemotherapy for pleural mesothelioma.

Making Chemotherapy More Effective

Strategy May Boost Mesothelioma Chemotherapy

The systemic, in addition to local, delivery of tumor targeted anti-TS RNAi system we propose...might be an effective option to extend the clinical utility of pemetrexed...

Scientists at Tokushima University have tested a method they say may improve mesothelioma survival by helping chemotherapy work better. Surviving Mesothelioma has just posted an article on the new research. Click here to read it now.

Doctors at the Institute of Health Biosciences took research they did last year a step further by testing a systemic (whole body) method of “reprogramming” mesothelioma cells to be more susceptible to the damaging effects of pemetrexed (brand name Alimta), the top mesothelioma drug.

“The systemic, in addition to local, delivery of tumor targeted anti-TS RNAi system we propose in this study might be an effective option to extend the clinical utility of pemetrexed in treating malignant mesothelioma,” writes Dr. Amr Abu Lila, lead author of the new study.

The research, published online by Molecular Pharmaceutics, used mouse models to demonstrate proof of concept. The next step will be to test the RNA interference (RNAi) method in human mesothelioma patients.

“Because nearly every person diagnosed with malignant mesothelioma will undergo treatment with pemetrexed at some point, we are always interested in any method that claims to be able to improve the effectiveness of this treatment,” says Alex Strauss, Managing Editor for Surviving Mesothelioma.

To learn more about RNAi and its potential impact on mesothelioma chemotherapy, see New Treatment Strategy Could Make Mesothelioma More Responsive to Chemotherapy, now available on the Surviving Mesothelioma website.

Abu Lila, AS, et al, “Systemically administered RNAi molecule sensitizes malignant pleural mesothelioma cells to pemetrexed therapy,” October 14, 2016, Epub ahead of print, http://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.6b00728

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website